BioSpace News Archive

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the Sachs Novel Coronavirus Investment Forum, being held July 7-9, 2020 with a focus on its CB5064 analogs targeting the coronavirus disease 2019 (COVID-19) associated ARDS. CohBa

Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melrose’s executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board. Dr. Melrose said: “Recce was formed with a mission to address the global health threat of antibiotic resistance and I feel we have made generationally s

Avanti combining with Croda to expand life sciences products, pharmaceutical services and cGMP production capabilities for biotechnology, pharmaceutical and life science research customers globally Avanti will continue to operate under the Avanti brand and be led by the current management team [06-July-2020] ALABASTER, Alabama , July 6, 2020 /PRNewswire/ --

Echosens , a high-technology company offering the FibroScan family of products, announces today that the National Institute for Health and Care Excellence ( NICE ), the United Kingdom’s health technology assessment body providing national guidance and advice to improve health and social care, issued a MedTech Innovation Briefing (MIB) dedicated to utilization of FibroScan non-invasive technology in the primary

Dragonfly expands beyond existing collaboration with Bristol Myers Squibb in oncology and autoimmune disease to develop drug candidates against multiple targets using its proprietary platform in new therapeutic areas WALTHAM, Mass., July 6, 202

Havn Life Sciences Inc. (the “Company” or “Havn Life”), announces the appointment of Gary Leong as Chief Science Officer of Havn Life. Mr. Leong has over thirty (30) years of experience in the Pharmaceutical and Natural Health Products (“NHP”) industry.

Neovasc, Inc. ( NASDAQ , TSX : NVCN) today announced preliminary revenue results for the second quarter of 2020. Revenue for the quarter ended June 30, 2020 was approximately $295,000. Revenues were negatively impacted by a reduction in Reducer procedures that began in mid-March and persisted through early June. Despite a marked slowdown in the num

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the start of a prospective, observational, global, multi-center, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in the treatment of thoracic aort

HOYA Corporation (TSE:7741, “HOYA”) and Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced a five year contract regarding Endoscopic Ultrasound Systems [EUS] by which, i) the parties will strengthen technical collaboration, and ii) Hitachi will continue supplying diagnostic ultrasound systems and ultrasound sensor related parts used in EUS.

Joint efforts aim to accelerate scale-up of WHO-recommended all-oral treatment regimens - a transition urgently needed to help protect the health of people with drug resistant-tuberculosis who are particularly vulnerable during COVID-19 pandemic